Upstream Bio, Inc. (UPB) income statement
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.59−0.41 (-20.50%)
Close on Nov 20, 2026Market cap $87.09MP/E –Yield –
Upstream Bio, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $87.09MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Margins | ||||
| Operating margin | -5,618.8% | -3,281.2% | -1,685.5% | – |
| EBITDA margin | -5,612.2% | -3,277.4% | -1,682.9% | – |
| Net profit margin | -5,026.0% | -2,650.0% | -862.9% | – |
| Free cash flow margin | -4,675.5% | -2,518.3% | -1,599.6% | – |
| Returns on capital | ||||
| Return on equity | -35.4% | -44.1% | 33.4% | – |
| Return on assets | -34.3% | -21.0% | -17.5% | – |
| Return on tangible assets | -34.3% | -21.0% | -17.5% | – |
| Return on capital employed | -39.5% | -26.7% | -36.2% | – |
| NOPAT | -$126.69M | -$61.43M | -$31.69M | – |
| Cash flow quality | ||||
| OCF / Sales | -4,669.8% | -2,496.7% | -1,593.5% | – |
| OCF / Net income | 0.93 | 0.94 | 1.85 | – |
| FCF / OCF | 100.1% | 100.9% | 100.4% | – |
| FCF / Net income | 0.93 | 0.95 | 1.85 | – |
| FCF / EBITDA | 83.3% | 76.8% | 95.0% | – |
| Unlevered free cash flow | -$133.44M | -$59.68M | -$38.07M | – |
| Levered free cash flow | -$133.44M | -$59.68M | -$38.07M | – |
| Efficiency | ||||
| Asset turnover | 0.01 | 0.01 | 0.02 | – |
| Fixed asset turnover | 5.00 | 6.40 | 14.97 | – |
| Receivables turnover | 4.46 | 6.67 | 24.29 | – |
| Days sales outstanding | 81.9 | 54.8 | 15.0 | – |
| CapEx to revenue | 5.8% | 21.6% | 6.1% | – |
| CapEx to OCF | -0.12% | -0.86% | -0.38% | – |
| CapEx to depreciation | 0.88 | 5.74 | 2.40 | – |
| Liquidity | ||||
| Current ratio | 26.15 | 44.63 | 17.96 | – |
| Quick ratio | 26.15 | 44.63 | 17.96 | – |
| Cash ratio | 25.39 | 43.82 | 16.85 | – |
| Working capital | $338.35M | $468.42M | $110.48M | – |
| Net current asset value | $337.80M | $467.29M | $107.61M | – |
| Leverage | ||||
| Assets to equity | 1.04 | 1.03 | -0.95 | – |
| Goodwill / Assets | – | 0.00% | – | – |
| Intangibles to total assets | – | 0.00% | – | – |
| Per share | ||||
| Revenue per share | 0.05 | 0.04 | 0.80 | – |
| EPS (basic) | -2.66 | -5.58 | -12.95 | – |
| EPS (diluted) | -2.66 | -5.58 | -12.95 | – |
| Book value per share | 6.26 | 8.77 | -41.15 | – |
| Tangible book value per share | 6.26 | 8.77 | -41.15 | – |
| Cash per share | 6.30 | 8.78 | 36.70 | – |
| Operating cash flow per share | -2.46 | -1.10 | -12.67 | – |
| Free cash flow per share | -2.46 | -1.11 | -12.72 | – |
| CapEx per share | 0.0030 | 0.0095 | 0.05 | – |
| Valuation at period end | ||||
| Market cap | $1.47B | $49.74M | – | – |
| Enterprise value | $1.09B | -$170.92M | – | – |
| P/S | 514x | 21.0x | – | – |
| P/B | 4.3x | 0.1x | – | – |
| P/TBV | 4.3x | 0.1x | – | – |
| P/OCF | -11.0x | -0.8x | – | – |
| EV/Sales | 383x | -72.1x | – | – |
| EV/EBITDA | – | 2.2x | – | – |
| EV/EBIT | – | 2.2x | – | – |
| EV/OCF | -8.2x | 2.9x | – | – |
| EV/FCF | – | 2.9x | – | – |
| Earnings yield | -9.8% | -126.3% | – | – |
| FCF yield | -9.1% | -120.0% | – | – |
| Cost structure | ||||
| R&D to revenue | 4,793.5% | 2,656.8% | 1,336.1% | – |
| Stock-based comp to revenue | 362.0% | 253.3% | 139.7% | – |
| Per employee | ||||
| Total employees | 75 | 52 | 52 | 52 |
| Revenue per employee | $38.05K | $45.58K | $45.77K | – |
| Operating profit per employee | -$2.14M | -$1.50M | -$771.42K | – |
| Net income per employee | -$1.91M | -$1.21M | -$394.94K | – |
| Free cash flow per employee | -$1.78M | -$1.15M | -$732.12K | – |
| Growth | ||||
| Revenue 1Y growth | 20.4% | -0.42% | – | – |
| EBIT 1Y growth | -106.2% | -93.9% | – | – |
| EBITDA 1Y growth | -106.2% | -93.9% | – | – |
| Net income 1Y growth | -128.4% | -205.8% | – | – |
| Diluted EPS 1Y growth | 52.3% | 56.9% | – | – |
| Operating cash flow 1Y growth | -125.2% | -56.0% | – | – |
| Free cash flow 1Y growth | -123.6% | -56.8% | – | – |
| CapEx 1Y growth | -67.7% | 254.9% | – | – |
| Total assets 1Y growth | -26.6% | 311.0% | – | – |
| Total equity 1Y growth | -27.7% | 481.6% | -16.0% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.